ATE250670T1 - Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen - Google Patents

Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen

Info

Publication number: ATE250670T1
Authority: AT; Austria
Prior art keywords: iii; present; rna; polymerase iii; rna polymerase
Prior art date: 1993-07-06

Application number

AT93401745T

Other languages

English (en)

Inventor

Alain Doglio

Jean-Claude Lefebvre

Laurence Cagnon

Original Assignee

Univ Nice Sophia Antipolis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-06

Filing date

1993-07-06

Publication date

2003-10-15

1993-07-06 Application filed by Univ Nice Sophia Antipolis filed Critical Univ Nice Sophia Antipolis

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE250670T1 publication Critical patent/ATE250670T1/de

Links

239000013598 vector Substances 0.000 title abstract 4
241000700605 Viruses Species 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102000014450 RNA Polymerase III Human genes 0.000 abstract 3
108010078067 RNA Polymerase III Proteins 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 3
108091034117 Oligonucleotide Proteins 0.000 abstract 2
108700005077 Viral Genes Proteins 0.000 abstract 2
210000003527 eukaryotic cell Anatomy 0.000 abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000001963 growth medium Substances 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000003834 intracellular effect Effects 0.000 abstract 1
229940126601 medicinal product Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000013518 transcription Methods 0.000 abstract 1
230000035897 transcription Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT93401745T 1993-07-06 1993-07-06 Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen ATE250670T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP93401745A EP0647716B1 (de)	1993-07-06	1993-07-06	Vektor, enthält ein bei ARN-Polymerase-III transcriptes Virus-Gen

Publications (1)

Publication Number	Publication Date
ATE250670T1 true ATE250670T1 (de)	2003-10-15

Family

ID=8214731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93401745T ATE250670T1 (de)	1993-07-06	1993-07-06	Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen

Country Status (3)

Country	Link
EP (1)	EP0647716B1 (de)
AT (1)	ATE250670T1 (de)
DE (1)	DE69333216T2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2743818B1 (fr) *	1996-01-23	1998-04-10	Agronomique Inst Nat Rech	Constructions d'adn et vecteurs d'expression derives du gene de l'arn va i d'adenovirus
US6291164B1 (en)	1996-11-22	2001-09-18	Invitrogen Corporation	Methods for preventing inhibition of nucleic acid synthesis by pyrophosphate
US6767699B2 (en)	2000-05-31	2004-07-27	Chiron Corporation	Method for the quantitation of alphavirus replicon particles
DE10046913A1 (de) *	2000-09-21	2002-04-18	Nascacell Gmbh	Expressionssystem für funktionale Nukleinsäuren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59010432D1 (de) *	1989-03-16	1996-09-05	Boehringer Ingelheim Int	Genetische Einheiten zur Inhibierung der Funktion von RNA
FR2687411A1 (fr) *	1992-02-13	1993-08-20	Nice Sophia Antipolis Universi	Vecteur comportant un gene viral transcrit par l'arn polymerase iii, et procede de production intracellulaire d'arn.

1993
- 1993-07-06 EP EP93401745A patent/EP0647716B1/de not_active Expired - Lifetime
- 1993-07-06 DE DE69333216T patent/DE69333216T2/de not_active Expired - Fee Related
- 1993-07-06 AT AT93401745T patent/ATE250670T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69333216D1 (de)	2003-10-30
EP0647716A1 (de)	1995-04-12
EP0647716B1 (de)	2003-09-24
DE69333216T2 (de)	2004-06-24

Similar Documents

Publication	Publication Date	Title
CY1111682T1 (el)	2015-10-07	Μεθοδοι και τροποι για την αποκτηση τροποποιημενων φαινοτυπων
ZA954451B (en)	1996-02-05	The cytoplasmic inhibition of gene expression
WO2004076622A3 (en)	2005-08-18	Regulation of gene expression by dna interference
ATE189264T1 (de)	2000-02-15	Chimärisches oligonukleotid und dessen verwendung zur herstellung von nukleinsäure-transkripten
CA2171759A1 (en)	1995-05-04	Methods and compositions for high protein production from recombinant dna
ATE192499T1 (de)	2000-05-15	Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren
WO1996001314A3 (de)	1996-02-29	Ribozym-bibliothek, ihre herstellung und ihre verwendung
GB2363794A (en)	2002-01-09	Anti-viral vectors
AU3824893A (en)	1993-11-04	Process for production of exogenous gene or its product in plant cells
ATE250670T1 (de)	2003-10-15	Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen
WO1994000463A3 (en)	1994-09-29	Production of hyaluronic acid by transeformed microorganisms
EP0242220A3 (en)	1989-05-03	Gene expression system
CA2037677A1 (en)	1992-03-08	Process for production of exogenous gene or its product in plant cells
EP0247145A4 (de)	1988-11-23	Vielfach amplifizierbare vektoren für hohe expression exogener dns.
GB2331989B (en)	2000-09-27	Retroviral vectors
KR970010968A (ko)	1997-03-27	오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
EP1728859B1 (de)	2011-05-04	Zur beschleunigung der genexpressionbei einer mässig niedrigen temperatur fähige sequenz
CA2289907A1 (en)	1998-11-12	Eukaryotic and retroviral antisense initiator elements
Thompson et al.	1990	Modulation of transcription by altered torsional stress, upstream silencers, and DNA-binding proteins.
IL92265A0 (en)	1990-07-26	Expression enhancer and employment thereof to increase the yield in the expression of recombinant genes
KR970001543A (ko)	1997-01-24	신규 프로모터 및 이를 이용한 유전자 발현 방법
Knowles et al.	1987	Recombinant DNA: Gene transfer and expression techniques with industrial yeast strains.
Miyagi et al.	2001	Replication of the rat aldolase B locus differs between aldolase B-expressing and non-expressing cells
Mulligan	1982	TRANSDUCTION OF GENES INTO ANIMAL CELLS.
Peranen	1992	Characterization of Semliki Forest virus nonstructural proteins.

Legal Events

Date	Code	Title	Description
2004-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties